Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for CRBP.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2013. Start Trial.
Date Value
June 30, 2026 102.24M
March 31, 2026 126.34M
December 31, 2025 147.50M
September 30, 2025 92.15M
June 30, 2025 110.99M
March 31, 2025 127.11M
December 31, 2024 142.43M
September 30, 2024 150.50M
June 30, 2024 125.54M
March 31, 2024 96.97M
December 31, 2023 -6.905M
September 30, 2023 0.311M
June 30, 2023 9.521M
March 31, 2023 16.46M
December 31, 2022 32.99M
September 30, 2022 41.95M
June 30, 2022 49.47M
March 31, 2022 61.16M
December 31, 2021 69.11M
September 30, 2021 77.63M
June 30, 2021 76.96M
March 31, 2021 91.52M
December 31, 2020 45.27M
September 30, 2020 29.23M
June 30, 2020 48.41M
Date Value
March 31, 2020 22.69M
December 31, 2019 6.158M
September 30, 2019 29.64M
June 30, 2019 47.37M
March 31, 2019 42.30M
December 31, 2018 27.52M
September 30, 2018 42.87M
June 30, 2018 55.49M
March 31, 2018 65.54M
December 31, 2017 57.78M
September 30, 2017 31.98M
June 30, 2017 37.59M
March 31, 2017 43.59M
December 31, 2016 8.919M
September 30, 2016 13.31M
June 30, 2016 17.65M
March 31, 2016 6.404M
December 31, 2015 8.985M
September 30, 2015 11.17M
June 30, 2015 6.769M
March 31, 2015 4.692M
December 31, 2014 5.863M
September 30, 2014 7.016M
June 30, 2014 7.450M
March 31, 2014

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 1.307B
Alnylam Pharmaceuticals, Inc. 1.354B
Anika Therapeutics, Inc. 137.28M
Savara, Inc. 143.66M
Vericel Corp. 370.04M

Shareholders Equity (Quarterly) Related Metrics